Cargando…
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expre...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/ https://www.ncbi.nlm.nih.gov/pubmed/36675262 http://dx.doi.org/10.3390/ijms24021746 |
_version_ | 1784876242166611968 |
---|---|
author | Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Bhatnagar, Gagan Pinato, David J. Ottensmeier, Christian Gomes, Fabio Banna, Giuseppe Luigi |
author_facet | Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Bhatnagar, Gagan Pinato, David J. Ottensmeier, Christian Gomes, Fabio Banna, Giuseppe Luigi |
author_sort | Anpalakhan, Shobana |
collection | PubMed |
description | GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC. This analysis follows on from the retrospective multicentre observational cohort Spinnaker study on advanced NSCLC patients. The primary endpoints were OS and PFS. The secondary endpoints were the frequency and severity of AEs and irAEs. Patient information, including GCSF use and NLR values, was collected. A secondary comparison with matched follow-up duration was also undertaken. Three hundred and eight patients were included. Median OS was 13.4 months in patients given GCSF and 12.6 months in those not (p = 0.948). Median PFS was 7.3 months in patients given GCSF and 8.4 months in those not (p = 0.369). A total of 56% of patients receiving GCSF had Grade 1–2 AEs compared to 35% who did not receive GCSF (p = 0.004). Following an assessment with matched follow-up, 41% of patients given GCSF experienced Grade 1–2 irAEs compared to 23% of those not given GCSF (p = 0.023). GCSF prophylaxis use did not significantly affect overall or progression-free survival. Patients given GCSF prophylaxis were more likely to experience Grade 1–2 adverse effects and Grade 1–2 immunotherapy-related adverse effects. |
format | Online Article Text |
id | pubmed-9867035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98670352023-01-22 The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Bhatnagar, Gagan Pinato, David J. Ottensmeier, Christian Gomes, Fabio Banna, Giuseppe Luigi Int J Mol Sci Article GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC. This analysis follows on from the retrospective multicentre observational cohort Spinnaker study on advanced NSCLC patients. The primary endpoints were OS and PFS. The secondary endpoints were the frequency and severity of AEs and irAEs. Patient information, including GCSF use and NLR values, was collected. A secondary comparison with matched follow-up duration was also undertaken. Three hundred and eight patients were included. Median OS was 13.4 months in patients given GCSF and 12.6 months in those not (p = 0.948). Median PFS was 7.3 months in patients given GCSF and 8.4 months in those not (p = 0.369). A total of 56% of patients receiving GCSF had Grade 1–2 AEs compared to 35% who did not receive GCSF (p = 0.004). Following an assessment with matched follow-up, 41% of patients given GCSF experienced Grade 1–2 irAEs compared to 23% of those not given GCSF (p = 0.023). GCSF prophylaxis use did not significantly affect overall or progression-free survival. Patients given GCSF prophylaxis were more likely to experience Grade 1–2 adverse effects and Grade 1–2 immunotherapy-related adverse effects. MDPI 2023-01-16 /pmc/articles/PMC9867035/ /pubmed/36675262 http://dx.doi.org/10.3390/ijms24021746 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Bhatnagar, Gagan Pinato, David J. Ottensmeier, Christian Gomes, Fabio Banna, Giuseppe Luigi The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title | The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title_full | The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title_fullStr | The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title_full_unstemmed | The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title_short | The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study |
title_sort | effects of gcsf primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a sub-analysis of the spinnaker study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/ https://www.ncbi.nlm.nih.gov/pubmed/36675262 http://dx.doi.org/10.3390/ijms24021746 |
work_keys_str_mv | AT anpalakhanshobana theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT huddarprerana theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT behrouziroya theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT signorialessio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cavejudith theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cominscharles theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cortellinialessio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT addeoalfredo theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT escriucarles theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT mckenziehayley theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT baronegloria theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT murraylisa theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT bhatnagargagan theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT pinatodavidj theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT ottensmeierchristian theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT gomesfabio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT bannagiuseppeluigi theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT anpalakhanshobana effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT huddarprerana effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT behrouziroya effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT signorialessio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cavejudith effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cominscharles effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT cortellinialessio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT addeoalfredo effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT escriucarles effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT mckenziehayley effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT baronegloria effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT murraylisa effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT bhatnagargagan effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT pinatodavidj effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT ottensmeierchristian effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT gomesfabio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy AT bannagiuseppeluigi effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy |